Universal Biosensors Inc - Asset Resilience Ratio

Latest as of June 2025: 14.72%

Universal Biosensors Inc (UBI) has an Asset Resilience Ratio of 14.72% as of June 2025. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing. Read UBI liabilities breakdown for a breakdown of total debt and financial obligations.

Liquid Assets

AU$2.20 Million
≈ $1.56 Million USD Cash + Short-term Investments

Total Assets

AU$14.94 Million
≈ $10.57 Million USD All company assets

Resilience Assessment

Moderate
Financial Resilience Level

Asset Resilience Ratio Trend (2007–2024)

This chart shows how Universal Biosensors Inc's Asset Resilience Ratio has changed over time. See UBI book value for net asset value and shareholders' equity analysis.

Liquid Assets Composition Over Time

This chart breaks down Universal Biosensors Inc's liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time. For market capitalisation and broader financial context, see Universal Biosensors Inc (UBI) market capitalisation.

Current Liquid Assets Breakdown

Component Amount % of Total Assets
Cash & Equivalents AU$2.20 Million 14.72%
Short-term Investments AU$0.00 0%
Total Liquid Assets AU$2.20 Million 14.72%

Asset Resilience Insights

  • Moderate Liquidity: Universal Biosensors Inc has 14.72% of assets in liquid form.
  • While adequate for normal operations, this level may limit flexibility during economic stress.
  • The company primarily holds liquidity in cash and equivalents rather than short-term investments.

Universal Biosensors Inc Industry Peers by Asset Resilience Ratio

Compare Universal Biosensors Inc's asset resilience ratio with other companies in the same industry.

Company Industry Asset Resilience Ratio
Vitrolife AB
ST:VITR
Medical Devices 7.27%
Medprin Regenerative Medical Technologies Co. Ltd.
SHE:301033
Medical Devices 19.31%
Tellgen Corp
SHE:300642
Medical Devices 8.60%
Lumos Diagnostics Holdings Ltd
AU:LDX
Medical Devices 9.40%
T&R Biofab Co. Ltd
KQ:246710
Medical Devices 0.12%
Ok Biotech Co Ltd
TW:4155
Medical Devices 0.32%
Promimic AB
ST:PRO
Medical Devices 8.62%
Memphasys Ltd
AU:MEM
Medical Devices 0.00%

Annual Asset Resilience Ratio for Universal Biosensors Inc (2007–2024)

The table below shows the annual Asset Resilience Ratio data for Universal Biosensors Inc.

Year Asset Resilience Ratio (%) Liquid Assets Total Assets Change
2024-12-31 33.06% AU$8.54 Million
≈ $6.05 Million
AU$25.84 Million
≈ $18.28 Million
-1.22pp
2023-12-31 34.28% AU$10.28 Million
≈ $7.27 Million
AU$29.97 Million
≈ $21.21 Million
-22.01pp
2022-12-31 56.30% AU$25.98 Million
≈ $18.38 Million
AU$46.15 Million
≈ $32.65 Million
+21.87pp
2021-12-31 34.42% AU$15.32 Million
≈ $10.84 Million
AU$44.50 Million
≈ $31.49 Million
-7.37pp
2020-12-31 41.79% AU$23.56 Million
≈ $16.67 Million
AU$56.38 Million
≈ $39.89 Million
-6.45pp
2019-12-31 48.24% AU$30.23 Million
≈ $21.39 Million
AU$62.66 Million
≈ $44.34 Million
+31.39pp
2018-12-31 16.86% AU$11.80 Million
≈ $8.35 Million
AU$69.98 Million
≈ $49.51 Million
-39.94pp
2017-12-31 56.80% AU$26.27 Million
≈ $18.59 Million
AU$46.26 Million
≈ $32.73 Million
+15.98pp
2016-12-31 40.81% AU$20.40 Million
≈ $14.44 Million
AU$49.99 Million
≈ $35.37 Million
+40.63pp
2011-12-31 0.18% AU$83.34K
≈ $58.97K
AU$45.22 Million
≈ $31.99 Million
-4.73pp
2007-12-31 4.92% AU$3.14 Million
≈ $2.22 Million
AU$63.86 Million
≈ $45.18 Million
--
pp = percentage points

About Universal Biosensors Inc

AU:UBI Australia Medical Devices
Market Cap
$2.95 Million
AU$4.17 Million AUD
Market Cap Rank
#29228 Global
#1704 in Australia
Share Price
AU$0.01
Change (1 day)
+0.00%
52-Week Range
AU$0.01 - AU$0.05
All Time High
AU$1.00
About

Universal Biosensors, Inc., through its subsidiaries, designs and develops electrochemical cells (strips) used in conjunction with point-of-use devices in Australia, the Americas, Europe, and internationally. The company manufactures and distributes Prothrombin Time International Normalized Ratio coagulation test strips and Xprecia Stride and Xprecia Prime medical devices to monitor the effect of… Read more